Thymoquinone in The clinical Treatment of cancer: Fact or fiction-

Pharmacognosy Reviews

Volumn 7, Issue 14, 2013, Pages 117-120

  Abukhader, Majed ^a  

^a OMAN MEDICAL COLLEGE   (Oman)

Author keywords

Breast cancer; drug delivery; pharmacokinetics; thymoquinone

Indexed keywords

DOXORUBICIN; PROTEIN; THYMOQUINONE;

ANTINEOPLASTIC ACTIVITY; BLACK CUMIN; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; GAMMA RADIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LD 50; MAXIMUM TOLERATED DOSE; NEOPLASM; NONHUMAN; REVIEW;

EID: 84889604662     PISSN: 09737847     EISSN: 09762787     Source Type: Journal    
DOI: 10.4103/0973-7847.120509     Document Type: Review

References (47)

1. Banning M. Advanced breast cancer: Aetiology, Treatment and psychosocial features. Br J Nurs 2007;16:86-90.
2. World Health Organisation. Breast cancer: Prevention and control, 2009. Available from: http://www.who.int/cancer/detection/breastcancer/en/index.html. [Last accessed on 2012 Dec].
3. CDC, US Cancer Statistics Working Group. Top 10 causes of death for women in The United States (2003). Atlanta CDC Statistics; 2007.
4. Farah IO, Begum RA. Effect of Nigella sativa (N. sativa L.) and oxidative stress on The survival pattern of MCF-7 breast cancer cells. Biomed Sci Instrum 2003;39:359-64. (Pubitemid 36433453)
5. Foster TS, Miller JD, Boye ME, Blieden MB, Gidwani R, Russell MW. The economic burden of metastatic breast cancer: A systematic review of literature from developed countries. Cancer Treat Rev 2011;37:405-15.
6. Mann J. Natural products in cancer chemotherapy: Past, present and future. Nat Rev Cancer 2002;2:143-8. (Pubitemid 37328801)
7. Gullett NP, Ruhul Amin AR, Bayraktar S, Pezzuto JM, Shin DM, Khuri FR, et al. Cancer prevention with natural compounds. Semin Oncol 2010;37:258-81.
8. Balachandran P, Govindarajan R. Cancer: An ayurvedic perspective. Pharmacol Res 2005;51:19-30.
9. Butt MS, Sultan MT. Nigella sativa: Reduces The risk of various maladies. Crit Rev Food Sci Nutr 2010;50:654-65.
10. Ilaiyaraja N, Khanum F. Nigella sativa L.: A review of Therapeutic application. J Herb Med Toxicol 2010;4:1-8.
11. Woo CC, Kumar AP, Sethi G, Tan KH. Thymoquinone: Potential cure for inflammatory disorders and cancer. Biochem Pharmacol 2012;83:443-51.
12. Banerjee S, Padhye S, Azmi A, Wang Z, Philip PA, Kucuk O, et al. Review on molecular and Therapeutic potential of Thymoquinone in cancer. Nutr Cancer 2010;62:938-46.
13. Padhye S, Banerjee S, Ahmad A, Mohammad R, Sarkar FH. From here To eternity-the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. Cancer Ther 2008;6:495-510.
14. Banerjee S, Parasramka M, Sarkar F, Mohammad R. Molecular insights and preclinical perspective of Thymoquinone as chemotherapeutic agent and Therapeutic adjuct in cancer. In: Shankar S, Srivastava R, editors. Nutrition, Deit and Cancer. Heidelberg: Springer Science; 2012. p. 83-103.
15. Attoub S, Sperandio O, Raza H, Arafat K, Al-Salam S, Al Sultan MA, et al. Thymoquinone as an anticancer agent: Evidence from inhibition of cancer cells viability and invasion in vitro and Tumor growth in vivo. Fundam Clin Pharmacol 2012.
16. Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of The pharmacologically active quinones and related compounds in The oil of The black seed (Nigella sativa L.). J Pharm Biomed Anal 1999;19:757-62. (Pubitemid 29092778)
17. Woo CC, Loo SY, Gee V, Yap CW, Sethi G, Kumar AP, et al. Anticancer activity of Thymoquinone in breast cancer cells: Possible involvement of PPAR-a pathway. Biochem Pharmacol 2011;82:464-75.
18. Kumar AP, Quake AL, Chang MK, Zhou T, Lim KS, Singh R, et al. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of The growth of Tumor cells in vitro and in vivo. Cancer Res 2009;69:8636-44.
19. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000;60:1129-38. (Pubitemid 30129556)
20. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor gamma by Troglitazone inhibits cell growth Through The increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000;60:5558-64.
21. Yin F, Wakino S, Liu Z, Kim S, Hsueh WA, Collins AR, et al. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by Targeting G1 cell cycle regulators. Biochem Biophys Res Commun 2001;286:916-22
22. Worthen DR, Ghosheh OA, Crooks PA. The in vitro anti-tumor activity of some crude and purified components of blackseed, Nigella sativa L. Anticancer Res 1998;18:1527-32. (Pubitemid 28342555)
23. Arafa el-SA, Zhu Q, Shah ZI, Wani G, Barakat BM, Racoma I, et al. Thymoquinone up-regulates PTEN expression and induces apoptosis in doxorubicin-resistant human breast cancer cells. Mutat Res 2011;706:28-35.
24. Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, et al. Inhibition of NF-kappa B activity in mammary epithelium increases Tumor latency and decreases Tumor burden. Oncogene 2011;30:1402-12.
25. Lee KH. Discovery and development of natural product-derived chemotherapeutic agents based on a medicinal chemistry approach. J Nat Prod 2010;73:500-16.
26. Qadri SM, Mahmud H, Föller M, Lang F. Thymoquinone-induced suicidal erythrocyte death. Food Chem Toxicol 2009;47:1545-9.
27. Badary O, Al-Shabanah OA, Nagi MN, Al-Bekairi AM, Almazar MM. Acute and subchronic Toxicity of Thymoquinone in mice. Drug Develop Res 1998;44:56-61. (Pubitemid 28452876)
28. Khader M, Bresgen N, Eckl PM. In vitro Toxicological properties of Thymoquinone. Food Chem Toxicol 2009;47:129-33.
29. Al-Ali A, Alkhawajah AA, Randhawa MA, Shaikh NA. Oral and intraperitoneal LD50 of Thymoquinone, an active principle of Nigella sativa, in mice and rats. J Ayub Med Coll Abbottabad 2008;20:25-7.
30. Mansour MA, Ginawi OT, El-Hadiyah T, El-Khatib AS, Al-Shabanah OA, Al-Sawaf HA. Effects of volatile oil constituents of Nigella sativa on carbon Tetrachloride-induced hepatotoxicity in mice: Evidence for antioxidant effects of Thymoquinone. Res Commun Mol Pathol Pharmacol 2001;110:239-51. (Pubitemid 36531687)
31. AbuKhader MM. The effect of route of administration in Thymoquinone Toxicity in male and female rats. Indian J Pharm Sci 2012;74:195-200.
32. Effenberger-Neidnicht K, Schobert R. Combinatorial effects of Thymoquinone on The anti-cancer activity of doxorubicin. Cancer Chemother Pharmacol 2011;67:867-74.
33. Ranson MR, Cheeseman S, White S, Margison J. Caelyx (stealth liposomal doxorubicin) in The Treatment of advanced breast cancer. Crit Rev Oncol Hematol 2001;37:115-20. (Pubitemid 32106910)
34. Nagi MN, Mansour MA. Protective effect of Thymoquinone against doxorubicin-induced cardiotoxicity in rats: A possible mechanism of protection. Pharmacol Res 2000;41:283-9. (Pubitemid 30663132)
35. al-Shabanah OA, Badary OA, Nagi MN, al-Gharably NM, al-Rikabi AC, al-Bekairi AM. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity. J Exp Clin Cancer Res 1998;17:193-8. (Pubitemid 28335578)
36. Velho-Pereira R, Kumar A, Pandey BN, Jagtap AG, Mishra KP. Radiosensitization in human breast carcinoma cells by Thymoquinone: Role of cell cycle and apoptosis. Cell Biol Int 2011;35:1025-9.
37. Lupidi G, Camaioni E, Khalifé H, Avenali L, Damiani E, Tanfani F, et al. Characterization of Thymoquinone binding To human á1-acid glycoprotein. J Pharm Sci 2012;101:2564-73.
38. Lupidi G, Scire A, Camaioni E, Khalife KH, De Sanctis G, Tanfani F, et al. Thymoquinone, a potential Therapeutic agent of Nigella sativa, binds To site I of human serum albumin. Phytomedicine 2010;17:714-20.
39. El-Najjar N, Ketola RA, Nissilä T, Mauriala T, Antopolsky M, Jänis J, et al. Impact of protein binding on The analytical detectability and anticancer activity of Thymoquinone. J Chem Biol 2011;4:97-107.
40. El-Najjar N, Ketola R, Urtti A, Gali-Muhtaseb H, Vuorela H. Impact of protein binding on Thymoquinone's analytical detection. Planta Med 2010;76:351.
41. Nagi MN, Almakki HA. Thymoquinone supplementation induces quinone reductase and glutathione Transferase in mice liver: Possible role in protection against chemical carcinogenesis and Toxicity. Phytother Res 2009;23:1295-8.
42. Ravindran J, Nair HB, Sung B, Prasad S, Tekmal RR, Aggarwal BB. Thymoquinone poly (lactide-co-glycolide) nanoparticles exhibit enhanced anti-proliferative, anti-inflammatory, and chemosensitization potential. Biochem Pharmacol 2010;79:1640-7.
43. Ganea GM, Fakayode SO, Losso JN, van Nostrum CF, Sabliov CM, Warner IM. Delivery of phytochemical Thymoquinone using molecular micelle modified poly (D, L lactide-co-glycolide) (PLGA) nanoparticles. Nanotechnology 2010;21:285104.
44. Odeh F, Ismail SI, Abu-Dahab R, Mahmoud IS, Al Bawab A. Thymoquinone in liposomes: A study of loading efficiency and biological activity Towards breast cancer. Drug Deliv 2012;19:371-7.
45. Al-Amri A, Bamosa A. Phase I safety and clinical activity study of Thymoquinone in patients with advanced refractory malignant disease. Shiraz E-Med J 2009;10:107-11.
46. Effenberger K, Breyer S, Schobert R. Terpene conjugates of The Nigella sativa seed-oil constituent Thymoquinone with enhanced efficacy in cancer cells. Chem Biodivers 2010;7:129-39.
47. Breyer S, Effenberger K, Schobert R. Effects of Thymoquinone-fatty acid conjugates on cancer cells. ChemMedChem 2009;4:761-8.